Download PDF
Semin Thromb Hemost 2002; 28(S1): 037-046
DOI: 10.1055/s-2002-30194
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Clinical Aspects of the Different Forms of Viral Hepatitis and Their Treatment

Tobias Goeser
  • Universitäts-Kliniken Köln, Köln, Germany
Further Information

Publication History

Publication Date:
17 May 2002 (online)

    Permissions and Reprints

About 30% of patients with chronic hepatitis C go on to develop liver cirrhosis within 20 years. With chronic hepatitis C, interferon-α only leads to elimination of the virus in about 10 to 25% of cases because relapse after the end of treatment is common. There is a growing body of data indicating that the incidence of relapse can be reduced by a longer course of treatment. Alternatively, relapses can be reduced by combination therapy with ribavirin, but we are awaiting the results of studies currently underway. One of the most important predictive factors is the hepatitis C virus (HCV) subtype. For predisposed subtypes, the indication for interferon therapy is overwhelming. Patients with chronic HCV-induced liver failure benefit from liver transplantation in spite of reinfection.

The fecal-oral infections transmitted with hepatitis A virus (HAV) and hepatitis E virus (HEV) normally resolve themselves without any consequences after the acute infection. With HAV infection, a second rise in transaminases is generally seen in the elderly, as is seen with rare cases (<1%) of subacute or fulminant hepatitis. Acute HEV infection occurs in Asia and South America as epidemic hepatitis and is a threat to pregnant women, up to 10% of whom can go on to develop fulminant hepatitis. In Germany, only rare cases of this type of hepatitis are seen, and these occur in vacationers.

On the other hand, the parentally transmitted forms of hepatitis due to hepatitis B virus (HBV), HCV, and hepatitis D virus (HDV) favor a chronic course to a greater or lesser degree, characterized by persistence of the virus and an increase in transaminases over more than 6 months. Worldwide, chronic viral hepatitis is the most common cause of chronic liver diseases, liver cirrhosis, and hepatocellular carcinoma. In adults, chronic forms of viral hepatitis and their consequences are indications for liver transplantation.

The GB-C virus, first described in 1995, is on occasion found in the serum of patients with chronic hepatitis and is virtually identical to hepatitis G virus (HGV). Occasionally, it appears that this virus is responsible for acute posttransfusion hepatitis. However, from the data currently available, there is some doubt as to whether this virus is actually a hepatitis virus in the strictest sense and whether it can lead to chronic hepatitis.[1] [2]

REFERENCES

  • 1 Alter H J, Nakatsuji Y, Melpolder J. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease.  N Engl J Med . 1997;  336 747-754
    CrossrefPubMedGoogle Scholar
  • 2 Alter M J, Gallagher M, Morris T. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection.  N Engl J Med . 1997;  336 741-746
    CrossrefPubMedGoogle Scholar
  • 3 Korenman J, Baker B, Waggoner J. Long-term remission of chronic hepatitis B after alpha-interferon therapy.  Ann Intern Med . 1991;  114 629-634
    PubMedGoogle Scholar
  • 4 Weissberg J L, Andres L L, Smith C I. Survival in chronic hepatitis B. An analysis of 379 patients.  Ann Intern Med . 1984;  101 613-616
    PubMedGoogle Scholar
  • 5 Liaw Y F, Tai D I, Chu C M, Chen T J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.  Hepatology . 1988;  8 493-496
    PubMedGoogle Scholar
  • 6 Viola L A, Barrison L G, Coleman C J, Paradinas F J, Murray-Lyon I M. The HBe antigen-antibody system and its relationship to clinical and laboratory findings in 100 chronic HBsAg carriers in Great Britain.  J Med Virol . 8 169-175
    PubMedGoogle Scholar
  • 7 Colombo M, de-Franchis R, Del-Ninno E. Hepatocellular carcinoma in Italian patients with cirrhosis.  N Engl J Med . 1991;  325 675-680
    CrossrefPubMedGoogle Scholar
  • 8 Niederau C, Heintges T, Lange S. Long-term follow-up of HbeAg-positive patients treated with interferon alpha for chronic hepatitis B (see comments).  N Engl J Med . 1996;  334 1422-1427
    CrossrefPubMedGoogle Scholar
  • 9 Carreno V, Castillo I, Molina J, Porres J C, Bartolome J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy.  J Hepatol . 1992;  5 102-106
    PubMedGoogle Scholar
  • 10 Lok A S, Chung H T, Liu V W, Ma O C. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha.  Gastroenterology . 1993;  105 1833-1838
    PubMedGoogle Scholar
  • 11 Hoofnagle J H, Peters M, Mullen K D. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B.  Gastroenterology . 1988;  95 1318-1325
    PubMedGoogle Scholar
  • 12 Brook M G, Karayiannis P, Thomas H C. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy?.  <~>A statistical analysis of predictive factors. Hepatology . 1989;  10 761-763
    PubMedGoogle Scholar
  • 13 Müller R, Baumgarten R, Markus R. Behandlung der chronischen Hepatitis B mit Interferon alpha-2b.  Dtsch Med Wochenschr . 1990;  115 403-407
    PubMedGoogle Scholar
  • 14 Perrillo R P, Schiff E R, Davis G L. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.  N Engl J Med . 1990;  323 295-301
    PubMedGoogle Scholar
  • 15 Wong D K, Cheung A M, O'Rourke K. Effect of alpha-interferon treatment in patients with HBe-Ag-positive chronic hepatitis B. A meta-analysis.  Ann Intern Med . 1993;  119 312-323
    PubMedGoogle Scholar
  • 16 Ruiz-Moreno M, Rua M J, Molina J. Prospective, randomized, controlled trial of interferon-alpha in children with chronic hepatitis B.  Hepatology . 1991;  13 1035-1039
    CrossrefPubMedGoogle Scholar
  • 17 Rossi S, Forleo M A, Hamad E L. Effectiveness and tolerability of prolonged interferon treatment in patients with HbsAg-positive chronic hepatitis.  Hepatology (Abst) . 1996;  24 569
    PubMedGoogle Scholar
  • 18 Marcellin P, Boyer N, Colin J F. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine.  Gut (Abst) . 1993;  34 S106
    CrossrefPubMedGoogle Scholar
  • 19 Conjeevaram H S, Hoofnagle J H, Austin H A. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alpha.  Gastroenterology . 1995;  109 540-546
    PubMedGoogle Scholar
  • 20 Guillevin L, Lhote F, Jarrousse B, Fain O. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years.  Ann Med Interne Paris . 1992;  143 405-416
    PubMedGoogle Scholar
  • 21 Perrillo R, Tamburro C, Regenstein F. Low-dose, titratable interferon alpha in decompensated liver disease caused by chronic infection with hepatitis B virus.  Gastroenterology . 1995;  109 908-916
    PubMedGoogle Scholar
  • 22 Lok A S, Wu P C, Lai C L. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B.  Gastroenterology . 1992;  102 2091-2097
    PubMedGoogle Scholar
  • 23 Dienstag J L, Schiff E R, Mitchell M. Extended lamivudine retreatment for chronic hepatitis B.  Hepatology (Abst) . 1996;  24 188A
    PubMedGoogle Scholar
  • 24 Samuel D, Müller R, Alexander G. Liver transplantation in European patients with the hepatitis B surface antigen.  N Engl J Med . 1993;  329 1842-1847
    CrossrefPubMedGoogle Scholar
  • 25 Farci P, Mandas A, Coiana A. Treatment of chronic hepatitis D with interferon alpha-2a.  N Engl J Med . 1994;  330 88-94
    CrossrefPubMedGoogle Scholar
  • 26 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C.  Lancet . 1997;  349 825-832
    CrossrefPubMedGoogle Scholar
  • 27 Goeser T, Muller H M, Solbach C. Hepatitis C virus, alcoholic cirrhosis, and hepatocellular carcinoma.  Cancer Epidemiol Biomarkers Prev . 1994;  3 311-315
    PubMedGoogle Scholar
  • 28 Kato Y, Nakata K, Omagari K. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses.  Cancer . 1994;  74 2234-2238
    PubMedGoogle Scholar
  • 29 Viladomiu L, Genesca J, Esteban J I. Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial.  Hepatology . 1992;  15 767-769
    PubMedGoogle Scholar
  • 30 Lampertico P, Rumi M, Romeo R. A multicenter randomized controlled trial of recombinant interferon-alpha-2b in patients with acute transfusion-associated hepatitis C.  Hepatology . 1994;  19 19-22
    CrossrefPubMedGoogle Scholar
  • 31 Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled dose study. Japan Acute Hepatitis Cooperative Study Group.  Gastroenterology . 1994;  107 805-811
    PubMedGoogle Scholar
  • 32 Davis G L, Balart L A, Schiff E R. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter, randomized, controlled trial. Hepatitis International Therapy Group.  N Engl J Med . 1989;  321 1501-1506
    PubMedGoogle Scholar
  • 33 Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.  Hepatology . 1996;  24 778-789
    PubMedGoogle Scholar
  • 34 Chemello L, Bonetti P, Cavalletto L. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group.  Hepatology . 1995;  22 700-706
    CrossrefPubMedGoogle Scholar
  • 35 Tsubota A, Chayama K, Ikeda K. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection.  Hepatology . 1994;  19 1088-1094
    CrossrefPubMedGoogle Scholar
  • 36 Serfaty L, Giral P, Loria A. Factors predictive of the response to interferon in patients with chronic hepatitis C.  J Hepatol . 1994;  21 12-17
    CrossrefPubMedGoogle Scholar
  • 37 Martinot-Peignoux M, Marcellin P, Pouteau M. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.  Hepatology . 1995;  22 1050-1056
    CrossrefPubMedGoogle Scholar
  • 38 Rumi M, Del-Ninno E, Parravicini M L. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alpha-2a as therapy for chronic hepatitis C.  Hepatology . 1996;  24 1366-1370
    PubMedGoogle Scholar
  • 39 Goeser T, Tox U, Müller H M, Arnold J C, Theilmann L. Bedeutung der Genotypen bei chronischer Hepatitis C Virusinfektion und Hepatitis C- bedingter Leberzirrhose.  Dtsch Med Wochenschr . 1995;  120 1070-1073
    PubMedGoogle Scholar
  • 40 Van-Thiel D H, Friedlander L, Fagiuoli S. Response to interferon is influenced by the iron content of the liver.  J Hepatol . 1994;  20 410-415
    CrossrefPubMedGoogle Scholar
  • 41 Kleter G E, Brouwer J T, Heijtink R A, Schalm S W, Quint W G. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon.  Antimicrob Agents Chemother . 1993;  37 595-597
    PubMedGoogle Scholar
  • 42 Saracco G, Abate M L, Baldi M. Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis.  Liver . 1994;  14 65-70
    PubMedGoogle Scholar
  • 43 Serfaty L, Chazouilleres O, Pawlotsky J M. Interferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity.  Gastroenterology . 1996;  110 291-295
    PubMedGoogle Scholar
  • 44 Bortolotti F, Giacchino R, Vajro P. Recombinant interferon-alpha therapy in children with chronic hepatitis C.  Hepatology . 1995;  22 1623-1627
    CrossrefPubMedGoogle Scholar
  • 45 Misiani R, Bellavita P, Fenili D. Interferon alpha-2a therapy in cryoglobulinemia associated with hepatitis C virus.  N Engl J Med . 1994;  330 751-756
    CrossrefPubMedGoogle Scholar
  • 46 Boyer N, Marcellin P, Degott C. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comite des Anti-Viraux.  J Infect Dis . 1992;  165 723-726
    PubMedGoogle Scholar
  • 47 Marriott E, Navas S, del-Romero J. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients.  J Med Virol . 1993;  40 107-111
    PubMedGoogle Scholar
  • 48 Rabinovitz M, Block G, Finkelstein S D. Alpha-interferon retreatment of patients with chronic hepatitis C.  Am J Gastroenterol . 1996;  91 1523-1526
    PubMedGoogle Scholar
  • 49 Di-Bisceglie A M, Conjeevaram H S, Fried M W. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med . 1995;  123 897-903
    CrossrefPubMedGoogle Scholar
  • 50 Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.  J Hepatol . 1995;  23(Suppl 2) 17-21
    PubMedGoogle Scholar
  • 51 Bellentani S, Podda M, Tiribelli C. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial.  J Hepatol . 1993;  19 459-464
    CrossrefPubMedGoogle Scholar
  • 52 Boucher E, Jouanolle H, Andre P. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.  Hepatology . 1995;  21 322-327
    CrossrefPubMedGoogle Scholar
  • 53 Arnold J C, Kraus T, Otto G. Recurrent hepatitis C virus infection after liver transplantation.  Transplant Proc . 1992;  24 2646-2647
    PubMedGoogle Scholar
  • 54 Ascher N L, Lake J R, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis.  Hepatology . 1994;  20 24S-27S
    CrossrefPubMedGoogle Scholar
  • 55 Feray C, Samuel D, Gigou M. An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection.  Hepatology . 1995;  22 1084-1089
    CrossrefPubMedGoogle Scholar
  • 56 Bizollon T, Ducerf C, Trepo C. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.  J Hepatol . 1995;  23(Suppl 2) 22-25
    PubMedGoogle Scholar
  • 57 Goeser T, Seipp S, Wahl R. Clinical presentation of GB-C virus in drug abusers with chronic hepatitis C.  J Hepatol . 1997;  26 498-502
    CrossrefPubMedGoogle Scholar
      >